Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ISR's Cash to Debt is ranked higher than
91% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. ISR: No Debt )
ISR' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: No Debt

Equity to Asset 0.79
ISR's Equity to Asset is ranked higher than
86% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. ISR: 0.79 )
ISR' s 10-Year Equity to Asset Range
Min: -1.18   Max: 0.91
Current: 0.79

-1.18
0.91
Interest Coverage No Debt
ISR's Interest Coverage is ranked higher than
86% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.61 vs. ISR: No Debt )
ISR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 32.04
M-Score: -2.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -89.88
ISR's Operating margin (%) is ranked lower than
51% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.44 vs. ISR: -89.88 )
ISR' s 10-Year Operating margin (%) Range
Min: -360.83   Max: -10.59
Current: -89.88

-360.83
-10.59
Net-margin (%) -85.24
ISR's Net-margin (%) is ranked higher than
50% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.65 vs. ISR: -85.24 )
ISR' s 10-Year Net-margin (%) Range
Min: -412.14   Max: -6.45
Current: -85.24

-412.14
-6.45
ROE (%) -71.88
ISR's ROE (%) is ranked lower than
51% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. ISR: -71.88 )
ISR' s 10-Year ROE (%) Range
Min: -284.75   Max: -42.28
Current: -71.88

-284.75
-42.28
ROA (%) -54.67
ISR's ROA (%) is ranked lower than
52% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.24 vs. ISR: -54.67 )
ISR' s 10-Year ROA (%) Range
Min: -6600   Max: 182500
Current: -54.67

-6600
182500
ROC (Joel Greenblatt) (%) -167.02
ISR's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. ISR: -167.02 )
ISR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -438.19   Max: -44.31
Current: -167.02

-438.19
-44.31
Revenue Growth (%) -17.30
ISR's Revenue Growth (%) is ranked higher than
54% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. ISR: -17.30 )
ISR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 12.2
Current: -17.3

0
12.2
EBITDA Growth (%) -11.50
ISR's EBITDA Growth (%) is ranked higher than
60% of the 210 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.40 vs. ISR: -11.50 )
ISR' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 205.5
Current: -11.5

0
205.5
EPS Growth (%) -15.10
ISR's EPS Growth (%) is ranked higher than
60% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. ISR: -15.10 )
ISR' s 10-Year EPS Growth (%) Range
Min: 0   Max: 97.6
Current: -15.1

0
97.6
» ISR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ISR



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 14.40
ISR's P/B is ranked lower than
77% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. ISR: 14.40 )
ISR' s 10-Year P/B Range
Min: 0.31   Max: 55
Current: 14.4

0.31
55
P/S 18.59
ISR's P/S is ranked lower than
87% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. ISR: 18.59 )
ISR' s 10-Year P/S Range
Min: 0.56   Max: 285
Current: 18.59

0.56
285
EV-to-EBIT 0.80
ISR's EV-to-EBIT is ranked higher than
98% of the 247 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.32 vs. ISR: 0.80 )
ISR' s 10-Year EV-to-EBIT Range
Min: 10.2   Max: 11.2
Current: 0.8

10.2
11.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 34.30
ISR's Price/Net Cash is ranked lower than
74% of the 68 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.30 vs. ISR: 34.30 )
ISR' s 10-Year Price/Net Cash Range
Min: 1   Max: 157.5
Current: 34.3

1
157.5
Price/Net Current Asset Value 26.70
ISR's Price/Net Current Asset Value is ranked lower than
69% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.00 vs. ISR: 26.70 )
ISR' s 10-Year Price/Net Current Asset Value Range
Min: 0.8   Max: 125
Current: 26.7

0.8
125
Price/Tangible Book 14.10
ISR's Price/Tangible Book is ranked lower than
80% of the 232 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. ISR: 14.10 )
ISR' s 10-Year Price/Tangible Book Range
Min: 0.35   Max: 51.79
Current: 14.1

0.35
51.79
Price/Median PS Value 3.40
ISR's Price/Median PS Value is ranked lower than
78% of the 268 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. ISR: 3.40 )
ISR' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 51
Current: 3.4

0.12
51
Earnings Yield (Greenblatt) 118.70
ISR's Earnings Yield (Greenblatt) is ranked higher than
96% of the 226 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. ISR: 118.70 )
ISR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 8.9   Max: 629.6
Current: 118.7

8.9
629.6
Forward Rate of Return (Yacktman) -28.74
ISR's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. ISR: -28.74 )
ISR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -45.4   Max: -38.3
Current: -28.74

-45.4
-38.3

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
IsoRay, Inc. was organized under Minnesota law in 1983, formerly known as Century Park Pictures Corporation On July 28, 2005, Century changed its name to IsoRay, Inc. The Company provides treatment for all solid tumor applications using Cesium-131 (Cs-131). Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; and breast, liver, brain and pancreatic cancer. The professional and patient market segments each play a role in the ultimate choice of cancer treatment and the specific isotope chosen for seed brachytherapy treatment. In August 2009, IsoRay Medical obtained treatment for Proxcelan(tm) Cesium-131 brachytherapy seeds that are preloaded into bioabsorbable braided strands. Brachytherapy seeds are small devices used in a radiation procedure. IsoRay markets the Proxcelan Cs-131 brachytherapy seed for the treatment of prostate cancer, ocular melanomas, and head and neck cancers, and intends to market Cs-131 for the treatment of other malignant disease, such as lung, in the near future. The Company competes with both public and private medical device, biotechnology and pharmaceutical companies. The disposal of certain radioactive substances and wastes are subject to regulation by several federal and state agencies depending on the nature of the substance or waste material.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide